title: NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.
abstract: The NF-κB pathway, a critical regulator of apoptosis, plays a key role in many normal cellular functions. Genetic alterations and other mechanisms leading to constitutive activation of the NF-κB pathway contribute to cancer development, progression and therapy resistance by activation of downstream anti-apoptotic pathways, unfavorable microenvironment interactions, and gene dysregulation. Not surprisingly, given its importance to normal and cancer cell function, the NF-κB pathway has emerged as a target for therapy. In the review, we present the physiologic role of the NF-κB pathway and recent advances in better understanding of the pathologic roles of the NF-κB pathway in major types of lymphoid neoplasms. We also provide an update of clinical trials that use NF-κB pathway inhibitors. These trials are exploring the clinical efficiency of combining NF-κB pathway inhibitors with various agents that target diverse mechanisms of action with the goal being to optimize novel therapeutic opportunities for targeting oncogenic pathways to eradicate cancer cells.
authors: Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA; Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
authors: Li
authors: L
authors: Yu
authors: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
authors: Ling
authors: L
authors: Li
authors: Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
authors: L Jeffrey
authors: LJ
authors: Medeiros
authors: Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA; The University of Texas Graduate School of Biomedical Science, Houston, TX, USA. Electronic address: khyoung@mdanderson.org.
authors: Ken H
authors: KH
authors: Young
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D002986:Clinical Trials as Topic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007945:Leukemia, Lymphoid / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism*; D008221:Lymphoid Tissue / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008223:Lymphoma / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism*; D058990:Molecular Targeted Therapy; D009154:Mutation; D016328:NF-kappa B / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects*; D016896:Treatment Outcome; D059016:Tumor Microenvironment
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D016328:NF-kappa B
keywords: Apoptosis; B-cell lymphoma; EBV; MiRNA; NF-κB pathway; Tumor microenvironment